Jpmorgan Chase & CO Nkarta, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Nkarta, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,063,362 shares of NKTX stock, worth $2.52 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,063,362
Previous 302,013
252.09%
Holding current value
$2.52 Million
Previous $1.78 Million
169.39%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding NKTX
# of Institutions
129Shares Held
66.5MCall Options Held
173KPut Options Held
20K-
Ra Capital Management, L.P. Boston, MA10.8MShares$25.6 Million0.68% of portfolio
-
Commodore Capital LP New York, NY4.66MShares$11 Million1.79% of portfolio
-
Black Rock Inc. New York, NY4.06MShares$9.62 Million0.0% of portfolio
-
Boxer Capital, LLC San Diego, CA4.03MShares$9.55 Million0.97% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA3.77MShares$8.93 Million9.87% of portfolio
About Nkarta, Inc.
- Ticker NKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,656,800
- Market Cap $115M
- Description
- Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...